## SPECIALTY QUANTITY LIMIT PROGRAM

# **VALCYTE** (valganciclovir)

### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.


### **II. COVERED QUANTITIES**

Medication	Standard Limit	FDA-recommended dosing
Valcyte (valganciclovir) 450 mg tablet	102 tablets per 30 days	Treatment of CMV Retinitis in Adults: Induction: 900 mg orally twice a day for 21 days Maintenance: 900 mg orally once a day
		Prevention of CMV Disease in Adults: 900 mg once a day
Valcyte (valganciclovir hydrochloride) for oral solution 50 mg/mL	1000 mL per 30 days	Prevention of CMV Disease in Pediatric Patients:  Dosage calculated based on BSA and CrCl given once a day, with maximum dose 900 mg

Abbreviations: CMV = cytomegalovirus; BSA = body surface area; CrCl = creatinine clearance


#### **III. REFERENCES**

1. Valcyte [package insert]. South San Francisco, CA: Genentech USA, Inc.; August 2018.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of